Knight Therapeutics | GUD - Loan Capital

Stock Price
7.55
Daily Change
0 0%
Monthly
-1.82%
Yearly
23.97%
Q2 Forecast
7.40

Knight Therapeutics reported CAD57.78M in Loan Capital for its fiscal quarter ending in December of 2025.





Loan Capital Change Date
Acasti Pharma USD 0 0 Dec/2024
Akebia Therapeutics USD 48.25M 609K Dec/2025
Alaunos Therapeutics USD 4.47M 5.85M Jun/2022
Aurora Cannabis CAD 33.2M 1.79M Dec/2025
Avita Medical AUD 42.24M 1.25M Dec/2024
Canopy Growth CAD 224.99M 1.34M Dec/2025
Dianthus Therapeutics USD 0 0 Dec/2024
Ionis Pharmaceuticals USD 1.91B 9M Mar/2026
IQVIA Holdings USD 13.99B 105M Mar/2026
Knight Therapeutics CAD 57.78M 26.92M Dec/2025
Moderna USD 603M 7M Mar/2026
Omeros USD 403.72M 27.2M Jun/2024
Organigram Holdings CAD 62.52M 13.88M Dec/2025
Organon & Co USD 8.55B 75M Mar/2026
Revvity USD 2.63B 543K Dec/2025
Tectonic Therapeutic USD 43K 57K Dec/2025
Tilray USD 268.59M 3.82M Sep/2025
Viatris USD 12.48B 7M Dec/2025
Xeris Pharmaceuticals USD 220.33M 866K Dec/2025